Abstract
siRNAs(Small interfering RNA) have emerged as new nucleic acid drugs to treat life-threatening diseases such as malignant tumors as our understanding of the molecular mechanisms of endogenous RNA interference has increased. Synthetic small interfering RNAs (siRNA) or short hairpin RNAs (shRNA) have been shown to have clinical potential in dental illnesses, eye infections, cancer, metabolic syndromes, neurological disorders, and other illnesses in subsequent RNAi investigations. Although various siRNA are used as a medication for respiratory and ophthalmic illnesses in clinical trials, there are problems in developing siRNA for malignancy treatments because systemic delivery would be required in the treatment of the majority of patients. Aside from nonspecific off-target effects and immunological stimulation issues, proper administration remains a significant challenge. The technologies that have been created for the formulation of siRNA therapeutics, including antisense oligonucleotides and plasmid DNA, have prepared the path for rapid advancement in in-vivo siRNA delivery. This review focuses on the Potential uses of siRNA in different diseases and its challenges in usage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
